Analyst Price Targets — QGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:38 am | — | Barclays | $44.00 | $41.91 | TheFly | Qiagen downgraded to Equal Weight from Overweight at Barclays |
| February 9, 2026 11:56 am | — | UBS | $52.00 | $50.95 | TheFly | Qiagen price target raised to $52 from $50 at UBS |
| February 6, 2026 2:50 pm | Cathy Ramsey Schulte | Robert W. Baird | $53.00 | $51.17 | TheFly | Qiagen price target raised to $53 from $48.42 at Baird |
| February 6, 2026 1:03 pm | — | Stifel Nicolaus | $50.00 | $51.25 | TheFly | Qiagen price target raised to $50 from $45 at Stifel |
| February 6, 2026 10:39 am | — | Barclays | $58.00 | $51.23 | TheFly | Qiagen price target raised to $58 from $55 at Barclays |
| February 5, 2026 8:44 pm | — | Jefferies | $59.00 | $51.23 | TheFly | Qiagen price target raised to $59 from $57 at Jefferies |
| January 22, 2026 8:09 am | Jan Koch | Deutsche Bank | $54.00 | $55.66 | StreetInsider | Deutsche Bank Downgrades Qiagen NV (QGEN) to Hold |
| December 15, 2025 10:56 am | — | Barclays | $57.89 | $47.64 | TheFly | Qiagen price target raised to $55 from $53 at Barclays |
| October 2, 2025 10:43 am | Catherine Ramsey Schulte | Barclays | $55.79 | $48.76 | TheFly | Qiagen price target lowered to $53 from $55 at Barclays |
| October 17, 2024 5:42 am | Shubhangi Gupt | HSBC | $51.58 | $45.48 | TheFly | Qiagen downgraded to Hold from Buy at HSBC |
Latest News for QGEN
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and…
HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17–21), where QIAGEN will…
Qiagen N.V. (NYSE: QGEN - Get Free Report) has been assigned an average rating of "Hold" from the twelve research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating on the
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome FFPE kits that are now shipping to customers. This new solution is a breakthrough that enables true whole transcriptome single cell RNA sequencing from formalin-fixed, paraffin-embedded samples.…
Allspring Global Investments Holdings LLC boosted its position in Qiagen N.V. (NYSE: QGEN) by 10.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,164,805 shares of the company's stock after purchasing an additional 290,449 shares during the period. Allspring Global Investments Holdings LLC
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for QGEN.
Senate Trading
No Senate trades found for QGEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.